Pharmaceutical & Life Sciences News

Carcinogen in Zantac Leads to Another Shipment Halt, Recall

Sept. 20, 2019, 3:14 PMUpdated: Sept. 20, 2019, 5:16 PM

A global effort to remove gastrointestinal medication tainted with a potential carcinogen from the market gained momentum, as one of India’s largest generic drugmakers halted shipments to customers worldwide and Italy ordered a recall of some medicine that originated in India.

Dr. Reddy’s Laboratories Ltd. said it is suspending all distribution of its ranitidine, the generic version of the Sanofi stomach drug Zantac, as a precautionary measure. The company expects “to provide an update in the coming days,” said spokeswoman Lori McCreary in an email.

Separately, the Italian Drug Agency said in a statement it was ordering a recall of...

To read the full article log in. To learn more about a subscription click here.